Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chidamide + linperlisib
- Development stage
- Phase 2
- Lead developer
- Yingli Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Chidamide + linperlisib is a combination drug regimen consisting of chidamide, a histone deacetylase (HDAC) inhibitor, and linperlisib, a phosphoinositide 3-kinase (PI3K) inhibitor. This combination is being investigated primarily for the treatment of refractory or relapsed peripheral T-cell lymphoma (PTCL) and follicular lymphoma. Chidamide works by inhibiting HDAC enzymes, leading to modulation of gene expression that can induce cancer cell apoptosis and inhibit proliferation. Linperlisib targets the PI3K pathway, which is involved in cell growth and survival signaling in cancer cells. The combination aims to enhance antitumor efficacy by simultaneously targeting epigenetic regulation and intracellular signaling pathways involved in lymphoma progression. Clinical trials are ongoing mainly in China to evaluate safety and efficacy[1][2][3][6].
- Brand names
- Itari
- Other names
- chidamide combined with linperlisib
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)PIK3CD (Phosphatidylinositol 3-kinase delta)
Beyond the preview
Go deeper on chidamide + linperlisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chidamide + linperlisib.